AbbVie Inc. (ABBV) is set to report its third-quarter earnings on Wednesday, with analysts expecting strong results. The company recently acquired Aliada Therapeutics, bolstering its Alzheimer’s research portfolio. We analyze AbbVie’s technical setup and analyst forecasts to see what lies ahead for the stock.